JMP Securities Downgrades Synta Pharma. (SNTA) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/4/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Cowen Downgrades Synta Pharma. (SNTA) to Market Perform
October 21, 2015 2:01 PM EDTCowen downgraded Synta Pharma. (NASDAQ: SNTA) from Outperform to Market Perform.
Analyst Boris Peaker commented, "In light of GALAXY-2's stoppage, we are downgrading shares of SNTA from Outperform to Market Perform without a price target. In our view there are limited... More
FBR Capital Downgrades Synta Pharma. (SNTA) to Market Perform Amid GALAXY-2 Termination
October 21, 2015 12:28 PM EDTFBR Capital downgraded Synta Pharma. (NASDAQ: SNTA) from Outperform to Market Perform and cuts its price target from $6 to $2.
Analyst Christopher James noted the following:
No separation of the curves following interim analysis. Following the termination of GALAXY-2, we do not see a clear path forward for ganetespib. Since the remaining studies with ganetespib are... MoreRoth Capital Downgrades Synta Pharma. (SNTA) to Neutral; $1 PT
October 21, 2015 8:41 AM EDTRoth Capital downgraded Synta Pharma. (NASDAQ: SNTA) from Buy to Neutral with a price target of $1.00 (from $13.00).
Analyst Joseph Pantginis commented, "GALAXY-2 has been terminated at the first interim for futility. This is quite disappointing news for ganetespib, and our call for... More
Synta Pharma (SNTA) Terminates Phase 3 GALAXY-2 Trial in Lung Cancer Due to Futility
October 21, 2015 7:25 AM EDTSynta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company has decided to terminate the Phase 3 GALAXY-2 trial of ganetespib and docetaxel in the second-line treatment of patients with advanced non-small cell lung adenocarcinoma. Based on the review of a pre-planned interim analysis, the studys Independent Data Monitoring Committee (IDMC) concluded that the addition of ganetespib to docetaxel is unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall survival compared to docetaxel alone. The IDMC noted... More
